Reed Jobs would rather talk about curing cancer than his last name

Reed Jobs says his venture firm Yosemite has grown to 17 people since launching nearly three years ago, as biotech rebounds from its post-pandemic slump. He highlighted expiring patents on major drugs and AI as forces creating new opportunities in cancer-focused investing.

Yosemite’s rapid expansion reflects renewed investor appetite for biotech after a difficult reset. The convergence of drug patent expirations and AI-driven discovery could accelerate competition around next-generation therapies, especially in oncology.